Biosimilar Drugs Substitution Trends in French Pharmacies

CHALLENGE

A leading strategy consulting firm, working with a client in the pharmaceutical industry, aims to assess the risk of substitution by delving into the go-to-market (GTM) strategies in France for biosimilars, with a specific focus on pharmacies.

BTHT APPROACH

BTHT analyzed the scope and key aspects of the project. The team promptly took action, conducting a thorough review of the competitive landscape and client profiles within the biosimilar drugs sector. The team then initiated the process of identifying and engaging top-tier market experts.

In a short time, the research team has reached a selective list of professionals who have extensive Biosimilars market expertise. BTHT's portfolio for this project included; - Former executives with a focus on commercial and sales strategies in French pharmaceutical groups and extensive experience in Biosimilars & OTCs. - Senior professionals at the interface of French pharmacies and laboratories, with expertise in biosimilar products substitution and drug marketing.

The team arranged 1-hour consultations, assisted experts and clients at every step and provided technical support to avoid any technical or other problems in the interviews.

OUTCOME

BTHT swiftly and comprehensively provided crucial insights to the client. The consultations with experienced experts illuminated the risks associated with biosimilar substitution in the French pharmaceutical landscape, particularly within pharmacies. With this comprehensive knowledge, the client is now equipped to make informed decisions, formulate effective strategies, and navigate the dynamic landscape of biosimilar drugs in France, optimizing their position within the market.